Page last updated: 2024-12-06

bergenin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Bergenin is a natural phenolic compound found in various plants, notably in the genus *Bergenia*. It exhibits a wide range of biological activities, including antioxidant, anti-inflammatory, antidiabetic, and anticancer properties. Research interest in bergenin stems from its potential therapeutic applications in treating various diseases. Studies have investigated its mechanisms of action, which involve modulation of signaling pathways related to inflammation, oxidative stress, and cell growth. Bergenin's synthesis can be achieved through various methods, including extraction from plant sources and chemical synthesis. Current research focuses on optimizing extraction processes and developing efficient synthetic routes for obtaining bergenin. Ongoing studies aim to further elucidate its pharmacological properties and explore its therapeutic potential in clinical settings.'

bergenin: RN refers to (2R-(2alpha,3beta,4alpha,4aalpha,10bbeta))-isomer; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID66065
CHEMBL ID273019
CHEBI ID69499
SCHEMBL ID893721
MeSH IDM0049466

Synonyms (71)

Synonym
bengenin
nsc661749
nsc-661749
pyrano[3,2-c][2]benzopyran-6(2h)-one, 3,4,4a,10b-tetrahydro-3,4,8,10-tetrahydroxy-2-(hydroxymethyl)-9-methoxy-, (2r,3s,4s,4ar,10bs)-
(2r,3s,4s,4ar,10bs)-3,4,8,10-tetrahydroxy-2-(hydroxymethyl)-9-methoxy-3,4,4a,10b-tetrahydro-2h-pyrano[3,2-c]isochromen-6-one
C09919
477-90-7
bergenin
D01040
bergenin (jan)
MLS001213180
smr000542844
vakerin
bergeninum
CHEMBL273019
chebi:69499 ,
nsc-757796
yanbaicaisu
3,4,8,10-tetrahydroxy-2-(hydroxymethyl)-9-methoxy-3,4,4a,10b-tetrahydro-2h-pyrano[3,2-c]isochromen-6-one hydrate
3,4,4a,10b-tetrahydro-3,4,8,10-tetrahydroxy-2-(hydroxymethyl)-9-methoxypyrano(3,2-c)(2)benzopyran-6(h)-one
bergenin [jan]
nsc 757796
l84rbe4idc ,
nsc 661749
unii-l84rbe4idc
4-methoxy-2-(tetrahydro-3,4,5-trihydroxy-6-(hydroxymethyl)pyran-2-yl)alpha-resorcylic acid gamma lactone
A827340
HMS2876J03
BERGENIN - CUSCUTIN
bdbm50349518
ardisic acid b
cuscutin
peltophorin
corylopsin
NCGC00346587-01
AKOS015896565
S2270
pyrano(3,2-c)(2)benzopyran-6(2h)-one, 3,4,4a,10b-tetrahydro-3,4,8,10-tetrahydroxy-2-(hydroxymethyl)-9-methoxy-(2r,3s,4s,4ar,10bs)-
bergenin [mi]
bergenin [who-dd]
bergeninum [chp]
bergenin [inci]
SCHEMBL893721
CCG-208553
CS-4946
DTXSID4048141
YWJXCIXBAKGUKZ-HJJNZUOJSA-N
(2r,3s,4s,4ar,10bs)-3,4,8,10-tetrahydroxy-2-(hydroxymethyl)-9-methoxy-3,4,4a,10b-tetrahydropyrano[3,2-c]isochromen-6(2h)-one
HY-N0017
bergenin, cuscutin
B4349
mfcd00133120
bergenin, analytical standard
SR-01000789834-6
SR-01000789834-5
sr-01000789834
bergenin, >=95% (lc/ms-elsd)
NCGC00346587-02
SW219117-1
(2r,3s,4s,4ar,10bs)-3,4,8,10-tetrahydroxy-2-(hydroxymethyl)-9-methoxy-2,3,4,4a-tetrahydropyrano[3,2-c]isochromen-6(10bh)-one
Q4891580
bergenin (cuscutin)
copylopsin,(s)
bergenitol
ardisinic acid
AS-16137
pyrano[3,2-c][2]benzopyran-6(2h)-one,3,4,4a,10b-tetrahydro-3,4,8,10-tetrahydroxy-2-(hydroxymethyl)-9-methoxy-, (2r,3s,4s,4ar,10bs)-
NCGC00346587-16
(2s,4r,5s,6s,7r)-5,6,12,14-tetrahydroxy-4-(hydroxymethyl)-13-methoxy-3,8-dioxatricyclo[8.4.0.0,2,7]tetradeca-1(10),11,13-trien-9-one
EN300-19651064
Z2037317034

Research Excerpts

Overview

Bergenin is a C-glycoside of 4-O-methylgallic acid with anti-inflammatory, antioxidant, and tissue-repairing abilities. Bergenin (BN) is a Biopharmaceutics Classification System class IV (BCS IV) drug with poor hydrophilicity and lipophilicity.

ExcerptReferenceRelevance
"Bergenin (1) is a C-glucoside of 4-O-methylgallic acid with known antiarthritic activity attributed to modulation of cytokine production. "( Antinociceptive properties of bergenin.
Couto, RD; David, JM; David, JP; de Lima, FO; de Oliveira, CM; Nonato, FR; Soares, MB; Villarreal, CF, 2011
)
2.1
"Bergenin is an isocoumarin natural product which aides in fat loss, healthy weight maintenance, enhancing the lipolytic effects of norepinephrine, inhibiting the formation of interleukin 1α and cyclooxygenases-2. "( Synthesis of new bergenin derivatives as potent inhibitors of inflammatory mediators NO and TNF-α.
Amin, H; Arfan, M; Choudhary, MI; Hussain, Z; Jabeen, A; Khan, IU; Mesaik, MA; Qadir, MI; Shah, MR; Soomro, S; VanDerveer, D, 2012
)
2.16
"Bergenin (BGN) is a C-glycoside of 4-O-methylgallic acid with anti-inflammatory, antioxidant, and tissue-repairing abilities. "( Bergenin has neuroprotective effects in mice with ischemic stroke through antioxidative stress and anti-inflammation via regulating Sirt1/FOXO3a/NF-κB signaling.
Neng, P; Wang, P; Xiong, Q; Yao, F; Zhang, F; Zhang, X, 2022
)
3.61
"Bergenin is a reportedly effective agent with antioxidative and antiapoptotic activity against acute injury."( Bergenin alleviates myocardial ischemia-reperfusion injury via SIRT1 signaling.
Cao, G; Li, P; Liu, Y; Shan, W; Shi, L; Song, Y; Sun, Y; Tan, Y; Yi, W; Zhang, B; Zhang, M; Zhou, H, 2023
)
3.07
"Bergenin (BG) is a polyphenolic substance which has therapeutic potential in the treatment of diabetic nephropathy (DN), a common complication of type II diabetes. "( Bergenin ameliorates diabetic nephropathy in C57BL/6 J mice by TLR4/MyD88/NF-κB signalling pathway regulation.
Chen, C; Hao, H; Quan, Y; Shangguan, C; Su, P; Yue, L, 2023
)
3.8
"Bergenin is a well-known active compound that exhibits antioxidant, antiarrhythmic, hepatoprotective, and anti-inflammatory activities. "( Effects of genetic variation and environmental factors on bergenin in Rodgersia sambucifolia Hemsl.
Guan, YH; Li, HT; Song, MF; Zhang, LX; Zhang, Y; Zhang, ZL, 2020
)
2.25
"Bergenin (BN) is a Biopharmaceutics Classification System class IV (BCS IV) drug with poor hydrophilicity and lipophilicity and is potentially eliminated by the efflux function of P-glycoprotein (P-gp). "( Evaluation of Intestinal Absorption and Bioavailability of a Bergenin-Phospholipid Complex Solid Dispersion in Rats.
Gao, H; Sun, Y; Wei, Y; Xi, L; Zhang, T, 2018
)
2.16
"Bergenin is a C-glycoside of 4-O-methylgallic acid that is isolated from medicinal plants such as Flueggea leucopyrus, Bergenia crassifolia, Mallotus philippensis, Corylopsis spicata, Caesalpinia digyna, Mallotus japonicus, and Sacoglottis gabonensis. "( Bergenin: a computationally proven promising scaffold for novel galectin-3 inhibitors.
Herath, C; Jayakody, RS; Perera, S; Wijewardhane, P, 2018
)
3.37
"Bergenin is an active constituent of the plants of genus Bergenia."( Bergenin Plays an Anti-Inflammatory Role via the Modulation of MAPK and NF-κB Signaling Pathways in a Mouse Model of LPS-Induced Mastitis.
Cao, YG; Gao, XJ; Guo, MY; Wang, TC; Zhang, NS; Zhang, ZC, 2015
)
2.58

Effects

Bergenin has been reported to exhibit hepatoprotective, anti-inflammatory, anticancer, neuroprotective, antiviral, and antimicrobial activities. Bergenin is isolated from a variety of tropical plants. It has several pharmacological applications in traditional Asian medicine.

ExcerptReferenceRelevance
"Bergenin has been reported to exhibit hepatoprotective, anti-inflammatory, anticancer, neuroprotective, antiviral, and antimicrobial activities."( Bergenin - A Biologically Active Scaffold: Nanotechnological Perspectives.
Bala, R; Dubey, AK; Kumar, D; Kumar, S; Madaan, R; Sharma, P; Shen, B; Singla, RK; Singla, S, 2022
)
2.89
"Bergenin, which has been isolated from a variety of tropical plants, has several pharmacological applications in traditional Asian medicine. "( How to easily replace the independent atom model - the example of bergenin, a potential anti-HIV agent of traditional Asian medicine.
Dittrich, B; Grabowsky, S; Hübschle, CB; Kalinowski, R; Luger, P; Weber, M, 2009
)
2.03

Actions

ExcerptReferenceRelevance
"Bergenin can inhibit glucose-induced ECM production in glomerular mesangial cells through the down-regulation of oxidative stress via the mTOR/β-TrcP/Nrf2 pathway, and it might be a candidate drug for the prevention and treatment of DN."( Bergenin impedes the generation of extracellular matrix in glomerular mesangial cells and ameliorates diabetic nephropathy in mice by inhibiting oxidative stress via the mTOR/β-TrcP/Nrf2 pathway.
Dai, Y; Liu, R; Lv, C; Miao, Y; Qiao, S; Tao, Y; Wei, Z; Xia, Y; Yue, M, 2019
)
2.68

Treatment

Bergenin treatment significantly (P<0.05) restored the activities of these complexes. Pretreatment with bergenin (14 days) in rats at three dose levels (20, 40 and 80 mg/kg; p.o.) significantly alleviated amnesia induced by scopolamine.

ExcerptReferenceRelevance
"Bergenin pretreatment yielded significant increases in intracellular calcium concentration, mitochondrial mass, mitochondrial membrane potential, and glyoxalase I reduced by MG."( Effect of bergenin on RANKL-induced osteoclast differentiation in the presence of methylglyoxal.
Choi, EM; Chon, S; Jung, WW; Suh, KS, 2019
)
1.64
"Bergenin treatment was initiated after LPS stimulation for 24 h."( Bergenin Plays an Anti-Inflammatory Role via the Modulation of MAPK and NF-κB Signaling Pathways in a Mouse Model of LPS-Induced Mastitis.
Cao, YG; Gao, XJ; Guo, MY; Wang, TC; Zhang, NS; Zhang, ZC, 2015
)
2.58
"Bergenin treatment significantly (P<0.05) restored the activities of these complexes."( Bergenin attenuates renal injury by reversing mitochondrial dysfunction in ethylene glycol induced hyperoxaluric rat model.
Aggarwal, D; Gautam, D; Sharma, M; Singla, SK, 2016
)
2.6
"Pretreatment with bergenin before MG exposure reduced MG-induced mitochondrial dysfunction by preventing mitochondrial membrane potential dissipation, loss of adenosine triphosphate and reduced adenosine monophosphate-activated protein kinase."( Effects of bergenin on methylglyoxal-induced damage in osteoblastic MC3T3-E1 cells.
Choi, EM; Lee, KH, 2018
)
1.19
"Pretreatment with bergenin (14 days) in rats at three dose levels (20, 40 and 80 mg/kg; p.o.) significantly (p < 0.01) and dose-dependently alleviated amnesia induced by scopolamine (2 mg/kg, i.p.)."( Neuroprotective effects of bergenin in Alzheimer's disease: Investigation through molecular docking, in vitro and in vivo studies.
Acharya, N; Acharya, S; Barai, P; Bhatt, H; Borisa, A; Raval, N, 2019
)
1.13
"Pretreatment with bergenin reduced the increased enzyme activities of alanine/aspartate aminotransferase, sorbitol dehydrogenase, gamma-glutamyltransferase and the elevated level of malondialdehyde induced by GalN."( Effects of bergenin, the major constituent of Mallotus japonicus against D-galactosamine-induced hepatotoxicity in rats.
Chang, MJ; Choi, HS; Choi, J; Kim, HS; Kim, SH; Lim, HK, 2001
)
1.02

Pharmacokinetics

The method is suitable for the determination of low bergenin concentration in human plasma after therapeutic oral doses. It has been first and successfully used for its pharmacokinetic studies in healthy Chinese volunteers.

ExcerptReferenceRelevance
" The main pharmacokinetic parameters indicated that bergenin exhibited a wide distribution and moderate elimination velocity in rat."( Determination and pharmacokinetic study of bergenin in rat plasma by RP-HPLC method.
Meng, QG; Shi, YB; Shi, YP, 2006
)
0.85
" The method is suitable for the determination of low bergenin concentration in human plasma after therapeutic oral doses, and has been first and successfully used for its pharmacokinetic studies in healthy Chinese volunteers."( Determination of bergenin in human plasma after oral administration by HPLC-MS/MS method and its pharmacokinetic study.
Guo, RC; Liu, H; Wang, BJ; Wang, J; Wei, CM; Yuan, GY; Zhang, R; Zhang, XM, 2009
)
0.94

Bioavailability

Nanotechnological concepts can be employed to overcome the poor bioavailability of bergenin. The C(max) and AUC(0-->infinity) of BPC were increased, and the relative bioavailability was significantly increased to 439%.

ExcerptReferenceRelevance
"To prepare a bergenin-phospholipid complex (BPC) to increase oral bioavailability of the drug."( Preparation, characterization and in vivo evaluation of bergenin-phospholipid complex.
Fan, TT; Gong, T; Huang, Y; Qin, X; Yang, Y; Zhang, XN, 2010
)
0.98
" The pharmacokinetic characteristics and bioavailability of BPC were investigated after oral administration in rats in comparison to bergenin and the physical mixture (bergenin and phospholipids)."( Preparation, characterization and in vivo evaluation of bergenin-phospholipid complex.
Fan, TT; Gong, T; Huang, Y; Qin, X; Yang, Y; Zhang, XN, 2010
)
0.81
" The C(max) and AUC(0-->infinity) of BPC were increased, and the relative bioavailability was significantly increased to 439% of bergenin."( Preparation, characterization and in vivo evaluation of bergenin-phospholipid complex.
Fan, TT; Gong, T; Huang, Y; Qin, X; Yang, Y; Zhang, XN, 2010
)
0.81
"The purpose of this study was to explore the absorption characteristics of bergenin (CAS 477-90-7) and to improve its bioavailability by modulation of the gastrointestinal (GI) absorption using two enhancers (borneol and Poloxamer 188, resp."( Oral characteristics of bergenin and the effect of absorption enhancers in situ, in vitro and in vivo.
Huang, Y; Qin, X; Yuan, F; Zhou, D, 2010
)
0.9
" It was found that bergenin and chlorogenic acid had typical extravascular administration concentration-time curves; flavonoids had a bimodal distribution improving bioavailability and extending the pharmacodynamics period."( An LC-MS/MS method for the simultaneous determination and pharmacokinetic studies of bergenin, chlorogenic acid and four flavonoids in rat plasma after oral administration of a QingGanSanJie decotion extract.
Chai, Y; Li, W; Lv, L; Qian, X; Zhang, G; Zhang, H; Zhao, L, 2014
)
0.95
"This study aimed to evaluate the potential of a novel glycoside non-ionic surfactant synthesized and characterized in our laboratory for increased oral bioavailability of Cefixime."( Glycoside-based niosomal nanocarrier for enhanced in-vivo performance of Cefixime.
Ahmad, F; Ali, I; Elhissi, AM; Imran, M; Nawaz, W; Sadiq, A; Shah, MR; Ullah, F; Ullah, S, 2016
)
0.43
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" Nanotechnological concepts can be employed to overcome the poor bioavailability of bergenin."( Bergenin - A Biologically Active Scaffold: Nanotechnological Perspectives.
Bala, R; Dubey, AK; Kumar, D; Kumar, S; Madaan, R; Sharma, P; Shen, B; Singla, RK; Singla, S, 2022
)
2.39

Dosage Studied

ExcerptRelevanceReference
" BRM-BG demonstrated to be safe and effective as carrier of Cefixime following oral dosing in rabbits."( Glycoside-based niosomal nanocarrier for enhanced in-vivo performance of Cefixime.
Ahmad, F; Ali, I; Elhissi, AM; Imran, M; Nawaz, W; Sadiq, A; Shah, MR; Ullah, F; Ullah, S, 2016
)
0.43
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
trihydroxybenzoic acid
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (6)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
chromobox protein homolog 1Homo sapiens (human)Potency89.12510.006026.168889.1251AID540317
Guanine nucleotide-binding protein GHomo sapiens (human)Potency50.11871.995325.532750.1187AID624287
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Polyphenol oxidase 2Agaricus bisporusIC50 (µMol)100.00000.03403.987110.0000AID1059453
Tumor necrosis factorHomo sapiens (human)IC50 (µMol)12.50000.20000.67911.3000AID1464043
AlbuminBos taurus (cattle)IC50 (µMol)163.60003.00003.00003.0000AID609798
Interleukin-6Homo sapiens (human)IC50 (µMol)0.20800.02300.11550.2080AID1464042
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (241)

Processvia Protein(s)Taxonomy
positive regulation of gene expressionTumor necrosis factorHomo sapiens (human)
negative regulation of gene expressionTumor necrosis factorHomo sapiens (human)
positive regulation of MAP kinase activityTumor necrosis factorHomo sapiens (human)
positive regulation of MAPK cascadeTumor necrosis factorHomo sapiens (human)
positive regulation of interleukin-33 productionTumor necrosis factorHomo sapiens (human)
positive regulation of cytokine production involved in inflammatory responseTumor necrosis factorHomo sapiens (human)
negative regulation of miRNA transcriptionTumor necrosis factorHomo sapiens (human)
positive regulation of miRNA transcriptionTumor necrosis factorHomo sapiens (human)
negative regulation of signaling receptor activityTumor necrosis factorHomo sapiens (human)
negative regulation of transcription by RNA polymerase IITumor necrosis factorHomo sapiens (human)
positive regulation of gene expressionTumor necrosis factorHomo sapiens (human)
negative regulation of gene expressionTumor necrosis factorHomo sapiens (human)
positive regulation of interleukin-8 productionTumor necrosis factorHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processTumor necrosis factorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IITumor necrosis factorHomo sapiens (human)
positive regulation of NF-kappaB transcription factor activityTumor necrosis factorHomo sapiens (human)
positive regulation of calcineurin-NFAT signaling cascadeTumor necrosis factorHomo sapiens (human)
positive regulation of cytokine production involved in inflammatory responseTumor necrosis factorHomo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionTumor necrosis factorHomo sapiens (human)
positive regulation of synoviocyte proliferationTumor necrosis factorHomo sapiens (human)
positive regulation of I-kappaB phosphorylationTumor necrosis factorHomo sapiens (human)
negative regulation of apoptotic signaling pathwayTumor necrosis factorHomo sapiens (human)
negative regulation of transcription by RNA polymerase IITumor necrosis factorHomo sapiens (human)
response to hypoxiaTumor necrosis factorHomo sapiens (human)
microglial cell activationTumor necrosis factorHomo sapiens (human)
positive regulation of cytokine productionTumor necrosis factorHomo sapiens (human)
positive regulation of protein phosphorylationTumor necrosis factorHomo sapiens (human)
negative regulation of endothelial cell proliferationTumor necrosis factorHomo sapiens (human)
negative regulation of L-glutamate import across plasma membraneTumor necrosis factorHomo sapiens (human)
macrophage activation involved in immune responseTumor necrosis factorHomo sapiens (human)
chronic inflammatory response to antigenic stimulusTumor necrosis factorHomo sapiens (human)
leukocyte migration involved in inflammatory responseTumor necrosis factorHomo sapiens (human)
regulation of immunoglobulin productionTumor necrosis factorHomo sapiens (human)
negative regulation of cytokine production involved in immune responseTumor necrosis factorHomo sapiens (human)
positive regulation of chronic inflammatory response to antigenic stimulusTumor necrosis factorHomo sapiens (human)
positive regulation of humoral immune response mediated by circulating immunoglobulinTumor necrosis factorHomo sapiens (human)
skeletal muscle contractionTumor necrosis factorHomo sapiens (human)
negative regulation of systemic arterial blood pressureTumor necrosis factorHomo sapiens (human)
glucose metabolic processTumor necrosis factorHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processTumor necrosis factorHomo sapiens (human)
inflammatory responseTumor necrosis factorHomo sapiens (human)
humoral immune responseTumor necrosis factorHomo sapiens (human)
JNK cascadeTumor necrosis factorHomo sapiens (human)
circadian rhythmTumor necrosis factorHomo sapiens (human)
extrinsic apoptotic signaling pathway via death domain receptorsTumor necrosis factorHomo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damageTumor necrosis factorHomo sapiens (human)
response to xenobiotic stimulusTumor necrosis factorHomo sapiens (human)
response to virusTumor necrosis factorHomo sapiens (human)
response to salt stressTumor necrosis factorHomo sapiens (human)
response to fructoseTumor necrosis factorHomo sapiens (human)
negative regulation of heart rateTumor necrosis factorHomo sapiens (human)
vascular endothelial growth factor productionTumor necrosis factorHomo sapiens (human)
positive regulation of gene expressionTumor necrosis factorHomo sapiens (human)
negative regulation of gene expressionTumor necrosis factorHomo sapiens (human)
negative regulation of lipid storageTumor necrosis factorHomo sapiens (human)
response to activityTumor necrosis factorHomo sapiens (human)
regulation of metabolic processTumor necrosis factorHomo sapiens (human)
calcium-mediated signalingTumor necrosis factorHomo sapiens (human)
extracellular matrix organizationTumor necrosis factorHomo sapiens (human)
osteoclast differentiationTumor necrosis factorHomo sapiens (human)
sequestering of triglycerideTumor necrosis factorHomo sapiens (human)
cortical actin cytoskeleton organizationTumor necrosis factorHomo sapiens (human)
positive regulation of protein-containing complex assemblyTumor necrosis factorHomo sapiens (human)
positive regulation of fever generationTumor necrosis factorHomo sapiens (human)
negative regulation of myelinationTumor necrosis factorHomo sapiens (human)
response to nutrient levelsTumor necrosis factorHomo sapiens (human)
negative regulation of interleukin-6 productionTumor necrosis factorHomo sapiens (human)
positive regulation of chemokine productionTumor necrosis factorHomo sapiens (human)
positive regulation of fractalkine productionTumor necrosis factorHomo sapiens (human)
positive regulation of type II interferon productionTumor necrosis factorHomo sapiens (human)
positive regulation of interleukin-1 beta productionTumor necrosis factorHomo sapiens (human)
positive regulation of interleukin-18 productionTumor necrosis factorHomo sapiens (human)
positive regulation of interleukin-6 productionTumor necrosis factorHomo sapiens (human)
positive regulation of interleukin-8 productionTumor necrosis factorHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationTumor necrosis factorHomo sapiens (human)
tumor necrosis factor-mediated signaling pathwayTumor necrosis factorHomo sapiens (human)
positive regulation of heterotypic cell-cell adhesionTumor necrosis factorHomo sapiens (human)
toll-like receptor 3 signaling pathwayTumor necrosis factorHomo sapiens (human)
negative regulation of myosin-light-chain-phosphatase activityTumor necrosis factorHomo sapiens (human)
response to isolation stressTumor necrosis factorHomo sapiens (human)
response to macrophage colony-stimulating factorTumor necrosis factorHomo sapiens (human)
vasodilationTumor necrosis factorHomo sapiens (human)
positive regulation of tyrosine phosphorylation of STAT proteinTumor necrosis factorHomo sapiens (human)
positive regulation of apoptotic processTumor necrosis factorHomo sapiens (human)
positive regulation of programmed cell deathTumor necrosis factorHomo sapiens (human)
regulation of canonical NF-kappaB signal transductionTumor necrosis factorHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionTumor necrosis factorHomo sapiens (human)
negative regulation of protein-containing complex disassemblyTumor necrosis factorHomo sapiens (human)
positive regulation of protein-containing complex disassemblyTumor necrosis factorHomo sapiens (human)
positive regulation of cysteine-type endopeptidase activity involved in apoptotic processTumor necrosis factorHomo sapiens (human)
positive regulation of MAP kinase activityTumor necrosis factorHomo sapiens (human)
positive regulation of MAPK cascadeTumor necrosis factorHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionTumor necrosis factorHomo sapiens (human)
positive regulation of JUN kinase activityTumor necrosis factorHomo sapiens (human)
positive regulation of neuron apoptotic processTumor necrosis factorHomo sapiens (human)
negative regulation of blood vessel endothelial cell migrationTumor necrosis factorHomo sapiens (human)
negative regulation of viral genome replicationTumor necrosis factorHomo sapiens (human)
positive regulation of nitric oxide biosynthetic processTumor necrosis factorHomo sapiens (human)
response to ethanolTumor necrosis factorHomo sapiens (human)
regulation of fat cell differentiationTumor necrosis factorHomo sapiens (human)
negative regulation of fat cell differentiationTumor necrosis factorHomo sapiens (human)
negative regulation of myoblast differentiationTumor necrosis factorHomo sapiens (human)
negative regulation of osteoblast differentiationTumor necrosis factorHomo sapiens (human)
positive regulation of osteoclast differentiationTumor necrosis factorHomo sapiens (human)
positive regulation of protein catabolic processTumor necrosis factorHomo sapiens (human)
positive regulation of action potentialTumor necrosis factorHomo sapiens (human)
positive regulation of cell adhesionTumor necrosis factorHomo sapiens (human)
positive regulation of mitotic nuclear divisionTumor necrosis factorHomo sapiens (human)
negative regulation of DNA-templated transcriptionTumor necrosis factorHomo sapiens (human)
positive regulation of DNA-templated transcriptionTumor necrosis factorHomo sapiens (human)
negative regulation of mitotic cell cycleTumor necrosis factorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IITumor necrosis factorHomo sapiens (human)
positive regulation of translational initiation by ironTumor necrosis factorHomo sapiens (human)
negative regulation of glucose importTumor necrosis factorHomo sapiens (human)
positive regulation of JNK cascadeTumor necrosis factorHomo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STATTumor necrosis factorHomo sapiens (human)
astrocyte activationTumor necrosis factorHomo sapiens (human)
embryonic digestive tract developmentTumor necrosis factorHomo sapiens (human)
positive regulation of smooth muscle cell proliferationTumor necrosis factorHomo sapiens (human)
positive regulation of inflammatory responseTumor necrosis factorHomo sapiens (human)
negative regulation of neurogenesisTumor necrosis factorHomo sapiens (human)
regulation of insulin secretionTumor necrosis factorHomo sapiens (human)
positive regulation of synaptic transmissionTumor necrosis factorHomo sapiens (human)
regulation of synapse organizationTumor necrosis factorHomo sapiens (human)
defense response to Gram-positive bacteriumTumor necrosis factorHomo sapiens (human)
cognitionTumor necrosis factorHomo sapiens (human)
leukocyte tethering or rollingTumor necrosis factorHomo sapiens (human)
detection of mechanical stimulus involved in sensory perception of painTumor necrosis factorHomo sapiens (human)
negative regulation of lipid catabolic processTumor necrosis factorHomo sapiens (human)
positive regulation of membrane protein ectodomain proteolysisTumor necrosis factorHomo sapiens (human)
positive regulation of DNA-binding transcription factor activityTumor necrosis factorHomo sapiens (human)
positive regulation of NF-kappaB transcription factor activityTumor necrosis factorHomo sapiens (human)
positive regulation of protein transportTumor necrosis factorHomo sapiens (human)
response to glucocorticoidTumor necrosis factorHomo sapiens (human)
positive regulation of hair follicle developmentTumor necrosis factorHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionTumor necrosis factorHomo sapiens (human)
regulation of synaptic transmission, glutamatergicTumor necrosis factorHomo sapiens (human)
positive regulation of glial cell proliferationTumor necrosis factorHomo sapiens (human)
positive regulation of vitamin D biosynthetic processTumor necrosis factorHomo sapiens (human)
positive regulation of calcidiol 1-monooxygenase activityTumor necrosis factorHomo sapiens (human)
epithelial cell proliferation involved in salivary gland morphogenesisTumor necrosis factorHomo sapiens (human)
regulation of branching involved in salivary gland morphogenesisTumor necrosis factorHomo sapiens (human)
negative regulation of vascular wound healingTumor necrosis factorHomo sapiens (human)
negative regulation of branching involved in lung morphogenesisTumor necrosis factorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeTumor necrosis factorHomo sapiens (human)
cellular response to lipopolysaccharideTumor necrosis factorHomo sapiens (human)
cellular response to amino acid stimulusTumor necrosis factorHomo sapiens (human)
cellular response to retinoic acidTumor necrosis factorHomo sapiens (human)
cellular response to nicotineTumor necrosis factorHomo sapiens (human)
cellular response to type II interferonTumor necrosis factorHomo sapiens (human)
cellular response to ionizing radiationTumor necrosis factorHomo sapiens (human)
positive regulation of mononuclear cell migrationTumor necrosis factorHomo sapiens (human)
positive regulation of podosome assemblyTumor necrosis factorHomo sapiens (human)
endothelial cell apoptotic processTumor necrosis factorHomo sapiens (human)
protein localization to plasma membraneTumor necrosis factorHomo sapiens (human)
negative regulation of oxidative phosphorylationTumor necrosis factorHomo sapiens (human)
inflammatory response to woundingTumor necrosis factorHomo sapiens (human)
extrinsic apoptotic signaling pathwayTumor necrosis factorHomo sapiens (human)
cellular response to toxic substanceTumor necrosis factorHomo sapiens (human)
liver regenerationTumor necrosis factorHomo sapiens (human)
necroptotic signaling pathwayTumor necrosis factorHomo sapiens (human)
negative regulation of bile acid secretionTumor necrosis factorHomo sapiens (human)
antiviral innate immune responseTumor necrosis factorHomo sapiens (human)
response to Gram-negative bacteriumTumor necrosis factorHomo sapiens (human)
positive regulation of neuroinflammatory responseTumor necrosis factorHomo sapiens (human)
negative regulation of amyloid-beta clearanceTumor necrosis factorHomo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionTumor necrosis factorHomo sapiens (human)
positive regulation of amyloid-beta formationTumor necrosis factorHomo sapiens (human)
response to L-glutamateTumor necrosis factorHomo sapiens (human)
positive regulation of neutrophil activationTumor necrosis factorHomo sapiens (human)
positive regulation of protein localization to plasma membraneTumor necrosis factorHomo sapiens (human)
regulation of establishment of endothelial barrierTumor necrosis factorHomo sapiens (human)
negative regulation of bicellular tight junction assemblyTumor necrosis factorHomo sapiens (human)
cellular response to amyloid-betaTumor necrosis factorHomo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferationTumor necrosis factorHomo sapiens (human)
positive regulation of leukocyte adhesion to vascular endothelial cellTumor necrosis factorHomo sapiens (human)
positive regulation of leukocyte adhesion to arterial endothelial cellTumor necrosis factorHomo sapiens (human)
regulation of membrane lipid metabolic processTumor necrosis factorHomo sapiens (human)
response to 3,3',5-triiodo-L-thyronineTumor necrosis factorHomo sapiens (human)
response to gold nanoparticleTumor necrosis factorHomo sapiens (human)
positive regulation of protein localization to cell surfaceTumor necrosis factorHomo sapiens (human)
positive regulation of blood microparticle formationTumor necrosis factorHomo sapiens (human)
positive regulation of chemokine (C-X-C motif) ligand 2 productionTumor necrosis factorHomo sapiens (human)
positive regulation of hepatocyte proliferationTumor necrosis factorHomo sapiens (human)
regulation of endothelial cell apoptotic processTumor necrosis factorHomo sapiens (human)
regulation of reactive oxygen species metabolic processTumor necrosis factorHomo sapiens (human)
positive regulation of DNA biosynthetic processTumor necrosis factorHomo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway in absence of ligandTumor necrosis factorHomo sapiens (human)
positive regulation of extrinsic apoptotic signaling pathwayTumor necrosis factorHomo sapiens (human)
cellular response to starvationAlbuminBos taurus (cattle)
negative regulation of mitochondrial depolarizationAlbuminBos taurus (cattle)
cellular response to calcium ion starvationAlbuminBos taurus (cattle)
positive regulation of NF-kappaB transcription factor activityInterleukin-6Homo sapiens (human)
positive regulation of platelet aggregationInterleukin-6Homo sapiens (human)
positive regulation of receptor signaling pathway via STATInterleukin-6Homo sapiens (human)
negative regulation of primary miRNA processingInterleukin-6Homo sapiens (human)
positive regulation of gene expressionInterleukin-6Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylationInterleukin-6Homo sapiens (human)
maintenance of blood-brain barrierInterleukin-6Homo sapiens (human)
positive regulation of MAPK cascadeInterleukin-6Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterleukin-6Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationInterleukin-6Homo sapiens (human)
cellular response to lipopolysaccharideInterleukin-6Homo sapiens (human)
positive regulation of leukocyte adhesion to vascular endothelial cellInterleukin-6Homo sapiens (human)
neutrophil apoptotic processInterleukin-6Homo sapiens (human)
germinal center B cell differentiationInterleukin-6Homo sapiens (human)
hepatic immune responseInterleukin-6Homo sapiens (human)
neutrophil mediated immunityInterleukin-6Homo sapiens (human)
monocyte chemotaxisInterleukin-6Homo sapiens (human)
positive regulation of immunoglobulin productionInterleukin-6Homo sapiens (human)
positive regulation of acute inflammatory responseInterleukin-6Homo sapiens (human)
positive regulation of leukocyte chemotaxisInterleukin-6Homo sapiens (human)
acute-phase responseInterleukin-6Homo sapiens (human)
inflammatory responseInterleukin-6Homo sapiens (human)
humoral immune responseInterleukin-6Homo sapiens (human)
positive regulation of cell population proliferationInterleukin-6Homo sapiens (human)
negative regulation of cell population proliferationInterleukin-6Homo sapiens (human)
vascular endothelial growth factor productionInterleukin-6Homo sapiens (human)
regulation of vascular endothelial growth factor productionInterleukin-6Homo sapiens (human)
positive regulation of vascular endothelial growth factor productionInterleukin-6Homo sapiens (human)
positive regulation of gene expressionInterleukin-6Homo sapiens (human)
positive regulation of epithelial to mesenchymal transitionInterleukin-6Homo sapiens (human)
negative regulation of lipid storageInterleukin-6Homo sapiens (human)
response to activityInterleukin-6Homo sapiens (human)
cytokine-mediated signaling pathwayInterleukin-6Homo sapiens (human)
platelet activationInterleukin-6Homo sapiens (human)
endocrine pancreas developmentInterleukin-6Homo sapiens (human)
neuron projection developmentInterleukin-6Homo sapiens (human)
response to peptidoglycanInterleukin-6Homo sapiens (human)
negative regulation of chemokine productionInterleukin-6Homo sapiens (human)
positive regulation of chemokine productionInterleukin-6Homo sapiens (human)
positive regulation of interleukin-1 beta productionInterleukin-6Homo sapiens (human)
positive regulation of interleukin-10 productionInterleukin-6Homo sapiens (human)
positive regulation of interleukin-17 productionInterleukin-6Homo sapiens (human)
positive regulation of interleukin-21 productionInterleukin-6Homo sapiens (human)
positive regulation of interleukin-6 productionInterleukin-6Homo sapiens (human)
positive regulation of interleukin-8 productionInterleukin-6Homo sapiens (human)
positive regulation of tumor necrosis factor productionInterleukin-6Homo sapiens (human)
negative regulation of collagen biosynthetic processInterleukin-6Homo sapiens (human)
positive regulation of T cell proliferationInterleukin-6Homo sapiens (human)
positive regulation of tyrosine phosphorylation of STAT proteinInterleukin-6Homo sapiens (human)
glucose homeostasisInterleukin-6Homo sapiens (human)
positive regulation of apoptotic processInterleukin-6Homo sapiens (human)
negative regulation of apoptotic processInterleukin-6Homo sapiens (human)
positive regulation of MAPK cascadeInterleukin-6Homo sapiens (human)
negative regulation of fat cell differentiationInterleukin-6Homo sapiens (human)
positive regulation of osteoblast differentiationInterleukin-6Homo sapiens (human)
positive regulation of translationInterleukin-6Homo sapiens (human)
regulation of angiogenesisInterleukin-6Homo sapiens (human)
negative regulation of bone resorptionInterleukin-6Homo sapiens (human)
positive regulation of DNA-templated transcriptionInterleukin-6Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterleukin-6Homo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STATInterleukin-6Homo sapiens (human)
positive regulation of smooth muscle cell proliferationInterleukin-6Homo sapiens (human)
negative regulation of neurogenesisInterleukin-6Homo sapiens (human)
regulation of insulin secretionInterleukin-6Homo sapiens (human)
defense response to Gram-negative bacteriumInterleukin-6Homo sapiens (human)
defense response to Gram-positive bacteriumInterleukin-6Homo sapiens (human)
positive regulation of B cell activationInterleukin-6Homo sapiens (human)
positive regulation of DNA-binding transcription factor activityInterleukin-6Homo sapiens (human)
response to glucocorticoidInterleukin-6Homo sapiens (human)
defense response to virusInterleukin-6Homo sapiens (human)
positive regulation of glial cell proliferationInterleukin-6Homo sapiens (human)
T follicular helper cell differentiationInterleukin-6Homo sapiens (human)
regulation of astrocyte activationInterleukin-6Homo sapiens (human)
neuron cellular homeostasisInterleukin-6Homo sapiens (human)
glucagon secretionInterleukin-6Homo sapiens (human)
regulation of glucagon secretionInterleukin-6Homo sapiens (human)
interleukin-6-mediated signaling pathwayInterleukin-6Homo sapiens (human)
cellular response to hydrogen peroxideInterleukin-6Homo sapiens (human)
T-helper 17 cell lineage commitmentInterleukin-6Homo sapiens (human)
hepatocyte proliferationInterleukin-6Homo sapiens (human)
positive regulation of extracellular matrix disassemblyInterleukin-6Homo sapiens (human)
inflammatory response to woundingInterleukin-6Homo sapiens (human)
liver regenerationInterleukin-6Homo sapiens (human)
cellular response to virusInterleukin-6Homo sapiens (human)
regulation of neuroinflammatory responseInterleukin-6Homo sapiens (human)
positive regulation of neuroinflammatory responseInterleukin-6Homo sapiens (human)
positive regulation of cytokine production involved in inflammatory responseInterleukin-6Homo sapiens (human)
positive regulation of apoptotic DNA fragmentationInterleukin-6Homo sapiens (human)
regulation of microglial cell activationInterleukin-6Homo sapiens (human)
positive regulation of T-helper 2 cell cytokine productionInterleukin-6Homo sapiens (human)
negative regulation of interleukin-1-mediated signaling pathwayInterleukin-6Homo sapiens (human)
positive regulation of type B pancreatic cell apoptotic processInterleukin-6Homo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (18)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingTumor necrosis factorHomo sapiens (human)
protease bindingTumor necrosis factorHomo sapiens (human)
cytokine activityTumor necrosis factorHomo sapiens (human)
tumor necrosis factor receptor bindingTumor necrosis factorHomo sapiens (human)
protein bindingTumor necrosis factorHomo sapiens (human)
death receptor agonist activityTumor necrosis factorHomo sapiens (human)
identical protein bindingTumor necrosis factorHomo sapiens (human)
oxygen bindingAlbuminBos taurus (cattle)
DNA bindingAlbuminBos taurus (cattle)
fatty acid bindingAlbuminBos taurus (cattle)
protein bindingAlbuminBos taurus (cattle)
toxic substance bindingAlbuminBos taurus (cattle)
pyridoxal phosphate bindingAlbuminBos taurus (cattle)
metal ion bindingAlbuminBos taurus (cattle)
enterobactin bindingAlbuminBos taurus (cattle)
interleukin-6 receptor bindingInterleukin-6Homo sapiens (human)
cytokine activityInterleukin-6Homo sapiens (human)
interleukin-6 receptor bindingInterleukin-6Homo sapiens (human)
protein bindingInterleukin-6Homo sapiens (human)
growth factor activityInterleukin-6Homo sapiens (human)
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (12)

Processvia Protein(s)Taxonomy
extracellular spaceTumor necrosis factorHomo sapiens (human)
phagocytic cupTumor necrosis factorHomo sapiens (human)
extracellular regionTumor necrosis factorHomo sapiens (human)
extracellular spaceTumor necrosis factorHomo sapiens (human)
plasma membraneTumor necrosis factorHomo sapiens (human)
external side of plasma membraneTumor necrosis factorHomo sapiens (human)
cell surfaceTumor necrosis factorHomo sapiens (human)
neuronal cell bodyTumor necrosis factorHomo sapiens (human)
membrane raftTumor necrosis factorHomo sapiens (human)
recycling endosomeTumor necrosis factorHomo sapiens (human)
cell surfaceTumor necrosis factorHomo sapiens (human)
extracellular regionAlbuminBos taurus (cattle)
extracellular spaceAlbuminBos taurus (cattle)
protein-containing complexAlbuminBos taurus (cattle)
extracellular spaceInterleukin-6Homo sapiens (human)
extracellular regionInterleukin-6Homo sapiens (human)
extracellular spaceInterleukin-6Homo sapiens (human)
endoplasmic reticulum lumenInterleukin-6Homo sapiens (human)
interleukin-6 receptor complexInterleukin-6Homo sapiens (human)
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (203)

Assay IDTitleYearJournalArticle
AID1059453Inhibition of mushroom tyrosinase using L-tyrosine as substrate preincubated for 10 mins followed by enzyme addition measured after 20 mins by microplate reader analysis2013Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24
Synthesis, antioxidant capacity, and structure-activity relationships of tri-O-methylnorbergenin analogues on tyrosinase inhibition.
AID1464046Solubility in pH 5.0 buffer2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
Synthesis, pH dependent, plasma and enzymatic stability of bergenin prodrugs for potential use against rheumatoid arthritis.
AID623637Antinociceptive activity against formalin-induced pain in mouse assessed as paw licking during early phase (0 to 10 mins) at 50 mg/kg, ip administered 40 mins before formalin challenge2011Journal of natural products, Oct-28, Volume: 74, Issue:10
Antinociceptive properties of bergenin.
AID623713Toxicity in mouse assessed as gastric ulcer at 100 mg/kg, ip for seven consecutive days relative to control2011Journal of natural products, Oct-28, Volume: 74, Issue:10
Antinociceptive properties of bergenin.
AID623640Antinociceptive activity against formalin-induced pain in mouse assessed as paw licking during early phase (0 to 10 mins) at 100 mg/kg, ip administered 40 mins before formalin challenge2011Journal of natural products, Oct-28, Volume: 74, Issue:10
Antinociceptive properties of bergenin.
AID623638Antinociceptive activity in ip dosed mouse assessed as inhibition of acetic acid-induced abdominal constrictions administered 40 mins before acetic acid challenge measured for 30 mins2011Journal of natural products, Oct-28, Volume: 74, Issue:10
Antinociceptive properties of bergenin.
AID623704Toxicity in mouse assessed as necrosis in gastric mucosa at 50 mg/kg, ip for seven consecutive days relative to control2011Journal of natural products, Oct-28, Volume: 74, Issue:10
Antinociceptive properties of bergenin.
AID1464040Solubility in water2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
Synthesis, pH dependent, plasma and enzymatic stability of bergenin prodrugs for potential use against rheumatoid arthritis.
AID400667Inhibition of monoclonal antibody ADP358/HIV1 gp120 interaction at 20 mg/mL1996Journal of natural products, Jun, Volume: 59, Issue:6
Constituents of Ardisia japonica and their in vitro anti-HIV activity.
AID1059449Inhibition of mushroom tyrosinase using L-tyrosine as substrate at 100 uM preincubated for 10 mins followed by enzyme addition measured after 20 mins by microplate reader analysis relative to control2013Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24
Synthesis, antioxidant capacity, and structure-activity relationships of tri-O-methylnorbergenin analogues on tyrosinase inhibition.
AID601457Antibacterial activity against Bacillus subtilis MTCC 441 at 2000 ug/ml after 24 hrs by agar-well diffusion method2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Evaluation of antioxidant and antimicrobial activities of Bergenin and its derivatives obtained by chemoenzymatic synthesis.
AID609798Antiglycation activity in bovine serum albumin assessed as inhibition of fructosamines formation in presence of glucose2011Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16
Synthesis and antiglycation potentials of bergenin derivatives.
AID609796Antiglycation activity assessed as inhibition of Schiff-base formation2011Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16
Synthesis and antiglycation potentials of bergenin derivatives.
AID1424159Antiproliferative activity against human PC3 cells incubated for 48 to 72 hrs by MTT assay2017European journal of medicinal chemistry, Jun-16, Volume: 133Synthesis and in vitro and in vivo antitumour activity study of 11-hydroxyl esterified bergenin/cinnamic acid hybrids.
AID1464050Stability in pH 7.4 PBS buffer assessed as compound remaining level at 120 mg/mL incubated for 24 hrs at 37 degC by HPLC method2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
Synthesis, pH dependent, plasma and enzymatic stability of bergenin prodrugs for potential use against rheumatoid arthritis.
AID400671Inhibition of monoclonal antibody ADP323/HIV1 gp120 c-terminal interaction1996Journal of natural products, Jun, Volume: 59, Issue:6
Constituents of Ardisia japonica and their in vitro anti-HIV activity.
AID623716Toxicity in mouse assessed as necrosis in gastric mucosa at 100 mg/kg, ip for seven consecutive days relative to control2011Journal of natural products, Oct-28, Volume: 74, Issue:10
Antinociceptive properties of bergenin.
AID1187218Immunosuppressive activity in BALB/c mouse assessed as reduction in SRBC-induced humoral immunity by measuring IgG level at 3 to 30 mg/kg, po administered once daily for 14 days measured 4 hrs post last dose2014Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
Pyrano-isochromanones as IL-6 inhibitors: synthesis, in vitro and in vivo antiarthritic activity.
AID623643Antinociceptive activity against formalin-induced pain in mouse assessed as paw licking during late phase (10 to 60 mins) at 100 mg/kg, ip administered 40 mins before formalin challenge2011Journal of natural products, Oct-28, Volume: 74, Issue:10
Antinociceptive properties of bergenin.
AID1187202Inhibition of LPS-induced TNFalpha production in human THP1 cells after 24 hrs2014Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
Pyrano-isochromanones as IL-6 inhibitors: synthesis, in vitro and in vivo antiarthritic activity.
AID1187216Antiarthritic activity in BALB/c mouse assessed as reduction in SRBC-induced blood IL2 level administered orally once daily for 14 days measured 4 hrs post last dose by ELISA method2014Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
Pyrano-isochromanones as IL-6 inhibitors: synthesis, in vitro and in vivo antiarthritic activity.
AID623692Antinociceptive activity against Freund's complete adjuvant-induced paw inflammation in IL10-deficient C57BL/6 mouse assessed as reduction in mechanical hyperalgesia at 100 mg/kg, ip administered 40 mins before CFA challenge measured 2 to 6 hrs2011Journal of natural products, Oct-28, Volume: 74, Issue:10
Antinociceptive properties of bergenin.
AID1187226Antiarthritic activity in DBA/1J mouse collagen-induced arthritis model assessed as reduction in TNFalpha level at 3 to 30 mg/kg, po administered once daily for 49 days starting from onset of disease and measured after 3 to 49 days of disease onset by ELI2014Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
Pyrano-isochromanones as IL-6 inhibitors: synthesis, in vitro and in vivo antiarthritic activity.
AID400659Cytotoxicity against human C8166 cells by XTT assay1996Journal of natural products, Jun, Volume: 59, Issue:6
Constituents of Ardisia japonica and their in vitro anti-HIV activity.
AID623698Toxicity in mouse assessed as liver function measuring serum AST level at 50 mg/kg, ip for seven consecutive days relative to control2011Journal of natural products, Oct-28, Volume: 74, Issue:10
Antinociceptive properties of bergenin.
AID1464041Partition coefficient, log P of the compound2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
Synthesis, pH dependent, plasma and enzymatic stability of bergenin prodrugs for potential use against rheumatoid arthritis.
AID623685Inhibition of IL1-beta production in Freund's complete adjuvant-induced mouse at 50 mg/kg, ip administered 40 mins before CFA challenge measured after 2 hrs by ELISA2011Journal of natural products, Oct-28, Volume: 74, Issue:10
Antinociceptive properties of bergenin.
AID400660Selectivity index, ratio of EC50 for HIV1 MN over TC50 for human C18166 cells1996Journal of natural products, Jun, Volume: 59, Issue:6
Constituents of Ardisia japonica and their in vitro anti-HIV activity.
AID601456Antibacterial activity against Staphylococcus aureus MTCC 2940 at 2000 ug/ml after 24 hrs by agar-well diffusion method2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Evaluation of antioxidant and antimicrobial activities of Bergenin and its derivatives obtained by chemoenzymatic synthesis.
AID656849Induction of LPS-B-induced TNF-alpha production in human THP1 cells at 60 uM after 4 hrs2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Synthesis of new bergenin derivatives as potent inhibitors of inflammatory mediators NO and TNF-α.
AID1187212Antiinflammatory activity in BALB/c mouse assessed as serum nitric oxide level at 10 mg/kg, po qd for 5 days followed by LPS challenge 1 hr after last compound dose on fifth day and measured 4 hrs post LPS challenge by Griess assay (Rvb = 6.95 +/- 1.81 uM2014Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
Pyrano-isochromanones as IL-6 inhibitors: synthesis, in vitro and in vivo antiarthritic activity.
AID315606Growth inhibition of human BGC823 cells at 5 uM after 72 hrs by MTT assay relative to control2008Bioorganic & medicinal chemistry, Feb-01, Volume: 16, Issue:3
Studies on the chemical constituents and anticancer activity of Saxifraga stolonifera (L) Meeb.
AID623708Toxicity in mouse assessed as renal function measuring serum creatinine level at 100 mg/kg, ip for seven consecutive days relative to control2011Journal of natural products, Oct-28, Volume: 74, Issue:10
Antinociceptive properties of bergenin.
AID1187223Antiarthritic activity in DBA/1J mouse collagen-induced arthritis model assessed as reduction in anticollagen antibody IgG2a level at 3 to 30 mg/kg, po administered once daily for 49 days starting from onset of disease and measured after 14 days of diseas2014Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
Pyrano-isochromanones as IL-6 inhibitors: synthesis, in vitro and in vivo antiarthritic activity.
AID1187236Inhibition of NFkappaB expression in human THP1 cells up to 100 uM by Western blotting method2014Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
Pyrano-isochromanones as IL-6 inhibitors: synthesis, in vitro and in vivo antiarthritic activity.
AID656843Antiinflammatory activity in human neutrophils assessed as inhibition of opsonized zymosan A-mediated superoxide anions production by WST-1 based respiratory burst assay2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Synthesis of new bergenin derivatives as potent inhibitors of inflammatory mediators NO and TNF-α.
AID400668Inhibition of monoclonal antibody ADP358/HIV1 gp120 interaction at 4 mg/mL1996Journal of natural products, Jun, Volume: 59, Issue:6
Constituents of Ardisia japonica and their in vitro anti-HIV activity.
AID1187219Immunosuppressive activity in BALB/c mouse assessed as reduction in SRBC-induced DTH response at 3 to 30 mg/kg, po administered once daily for 14 days measured 4 hrs post last dose2014Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
Pyrano-isochromanones as IL-6 inhibitors: synthesis, in vitro and in vivo antiarthritic activity.
AID623686Inhibition of IL1-beta production in Freund's complete adjuvant-induced mouse at 100 mg/kg, ip administered 40 mins before CFA challenge measured after 2 hrs by ELISA2011Journal of natural products, Oct-28, Volume: 74, Issue:10
Antinociceptive properties of bergenin.
AID623705Toxicity in mouse assessed as reduction in corporal mass at 100 mg/kg, ip for seven consecutive days relative to control2011Journal of natural products, Oct-28, Volume: 74, Issue:10
Antinociceptive properties of bergenin.
AID315609Growth inhibition of human BGC823 cells at 100 uM after 72 hrs by MTT assay relative to control2008Bioorganic & medicinal chemistry, Feb-01, Volume: 16, Issue:3
Studies on the chemical constituents and anticancer activity of Saxifraga stolonifera (L) Meeb.
AID1187210Antiinflammatory activity in BALB/c mouse assessed as serum IL6 level at 10 mg/kg, po qd for 5 days followed by LPS challenge 1 hr after last compound dose on fifth day and measured 4 hrs post LPS challenge by ELISA method (Rvb = 410 +/- 95 pg/mL)2014Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
Pyrano-isochromanones as IL-6 inhibitors: synthesis, in vitro and in vivo antiarthritic activity.
AID623710Toxicity in mouse assessed as liver function measuring serum AST level at 100 mg/kg, ip for seven consecutive days relative to control2011Journal of natural products, Oct-28, Volume: 74, Issue:10
Antinociceptive properties of bergenin.
AID402067Enhancement of norepinephrine-induced lipolysis in cell-free system consisting sonicated lipid droplets assessed as free fatty acid release at 1000 ug in presence of hormone-sensitive lipase relative to untreated control1998Journal of natural products, Aug, Volume: 61, Issue:8
Norepinephrine-augmenting lipolytic effectors from Astilbe thunbergii rhizomes.
AID1424161Antiproliferative activity against human SGC7901 cells incubated for 48 to 72 hrs by MTT assay2017European journal of medicinal chemistry, Jun-16, Volume: 133Synthesis and in vitro and in vivo antitumour activity study of 11-hydroxyl esterified bergenin/cinnamic acid hybrids.
AID400666Inhibition of monoclonal antibody ADP358/HIV1 gp120 interaction at 100 mg/mL1996Journal of natural products, Jun, Volume: 59, Issue:6
Constituents of Ardisia japonica and their in vitro anti-HIV activity.
AID400658Antiviral activity against HIV1 MN in human C8166 cells assessed as reduction of antigen gp120 production by ELISA1996Journal of natural products, Jun, Volume: 59, Issue:6
Constituents of Ardisia japonica and their in vitro anti-HIV activity.
AID402063Enhancement of norepinephrine-induced lipolysis in Wistar rat fat cells assessed as free fatty acid release per mL of packed fat cells after 1 hr relative to norepinephrine1998Journal of natural products, Aug, Volume: 61, Issue:8
Norepinephrine-augmenting lipolytic effectors from Astilbe thunbergii rhizomes.
AID623709Toxicity in mouse assessed as liver function measuring serum ALT level at 100 mg/kg, ip for seven consecutive days relative to control2011Journal of natural products, Oct-28, Volume: 74, Issue:10
Antinociceptive properties of bergenin.
AID1311784Antiinflammatory activity against LPS-stimulated mouse RAW264.7 cells assessed as downregulation of NO levels by ELISA2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
Anti-inflammatory polyphenol constituents derived from Cissus pteroclada Hayata.
AID1311785Antiinflammatory activity against LPS-stimulated mouse RAW264.7 cells assessed as downregulation of PGE2 levels by ELISA2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
Anti-inflammatory polyphenol constituents derived from Cissus pteroclada Hayata.
AID1187199Inhibition of LPS-induced cell proliferation of B cells (unknown origin) at 10 uM after 72 hrs by MTT assay2014Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
Pyrano-isochromanones as IL-6 inhibitors: synthesis, in vitro and in vivo antiarthritic activity.
AID623679Antinociceptive activity against Freund's complete adjuvant-induced paw inflammation in mouse assessed as reduction in paw edema at 100 mg/kg, ip administered 40 mins before CFA challenge measured after 4 hrs2011Journal of natural products, Oct-28, Volume: 74, Issue:10
Antinociceptive properties of bergenin.
AID623694Toxicity in mouse assessed as change in general appearance at 50 mg/kg, ip for seven consecutive days relative to control2011Journal of natural products, Oct-28, Volume: 74, Issue:10
Antinociceptive properties of bergenin.
AID1187222Antiarthritic activity in DBA/1J mouse collagen-induced arthritis model assessed as reduction in anticollagen antibody IgG1 level at 3 to 30 mg/kg, po administered once daily for 49 days starting from onset of disease and measured after 14 days of disease2014Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
Pyrano-isochromanones as IL-6 inhibitors: synthesis, in vitro and in vivo antiarthritic activity.
AID623668Neurotoxicity in mouse assessed as effect on motor coordination by measuring reduced latency at 100 mg/kg, ip after 40 mins by rotarod test2011Journal of natural products, Oct-28, Volume: 74, Issue:10
Antinociceptive properties of bergenin.
AID623707Toxicity in mouse assessed as renal function measuring serum urea level at 100 mg/kg, ip for seven consecutive days relative to control2011Journal of natural products, Oct-28, Volume: 74, Issue:10
Antinociceptive properties of bergenin.
AID1187213Antiinflammatory activity in BALB/c mouse assessed as serum nitric oxide level at 100 mg/kg, po qd for 5 days followed by LPS challenge 1 hr after last compound dose on fifth day and measured 4 hrs post LPS challenge by Griess assay (Rvb = 6.95 +/- 1.81 u2014Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
Pyrano-isochromanones as IL-6 inhibitors: synthesis, in vitro and in vivo antiarthritic activity.
AID623693Toxicity in mouse assessed as reduction in corporal mass at 50 mg/kg, ip for seven consecutive days relative to control2011Journal of natural products, Oct-28, Volume: 74, Issue:10
Antinociceptive properties of bergenin.
AID400669Inhibition of monoclonal antibody ADP358/HIV1 gp120 interaction at 0.8 mg/mL1996Journal of natural products, Jun, Volume: 59, Issue:6
Constituents of Ardisia japonica and their in vitro anti-HIV activity.
AID609801Antiglycation activity assessed as inhibition of advanced glycation end product formation at 200 uM2011Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16
Synthesis and antiglycation potentials of bergenin derivatives.
AID623702Toxicity in mouse assessed as inflammatory cell infiltrate in gastric mucosa at 50 mg/kg, ip for seven consecutive days relative to control2011Journal of natural products, Oct-28, Volume: 74, Issue:10
Antinociceptive properties of bergenin.
AID1464043Inhibition of TNFalpha (unknown origin)2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
Synthesis, pH dependent, plasma and enzymatic stability of bergenin prodrugs for potential use against rheumatoid arthritis.
AID623684Effect on baseline nociceptive threshold in Freund's complete adjuvant-induced mouse at 50 to 100 mg/kg, ip administered 40 mins before CFA challenge measured 2 to 6 hrs2011Journal of natural products, Oct-28, Volume: 74, Issue:10
Antinociceptive properties of bergenin.
AID1464055Stability in in rat plasma assessed as compound remaining level at 120 mg/mL incubated for 4 hrs at 37 degC by HPLC method2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
Synthesis, pH dependent, plasma and enzymatic stability of bergenin prodrugs for potential use against rheumatoid arthritis.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1424163Antiproliferative activity against human HepG2 cells incubated for 48 to 72 hrs by MTT assay2017European journal of medicinal chemistry, Jun-16, Volume: 133Synthesis and in vitro and in vivo antitumour activity study of 11-hydroxyl esterified bergenin/cinnamic acid hybrids.
AID623714Toxicity in mouse assessed as inflammatory cell infiltrate in gastric mucosa at 100 mg/kg, ip for seven consecutive days relative to control2011Journal of natural products, Oct-28, Volume: 74, Issue:10
Antinociceptive properties of bergenin.
AID402064Induction of lipolysis in Wistar rat fat cells assessed as free fatty acid release per mL of packed fat cells after 1 hr relative to norepinephrine1998Journal of natural products, Aug, Volume: 61, Issue:8
Norepinephrine-augmenting lipolytic effectors from Astilbe thunbergii rhizomes.
AID1187208Antiinflammatory activity in BALB/c mouse assessed as serum TNFalpha level at 10 mg/kg, po qd for 5 days followed by LPS challenge 1 hr after last compound dose on fifth day and measured 4 hrs post LPS challenge by ELISA method (Rvb = 717 +/- 218 pg/mL)2014Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
Pyrano-isochromanones as IL-6 inhibitors: synthesis, in vitro and in vivo antiarthritic activity.
AID1853448Inhibition of ConA-induced IFN-gamma secretion in BALB/c mouse splenocyte at 10 uM incubated for 48 hrs by ELISA relative to control2021RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11
Synthesis and biological evaluation of bergenin derivatives as new immunosuppressants.
AID623680Antinociceptive activity against Freund's complete adjuvant-induced paw inflammation in mouse assessed as reduction in paw edema at 100 mg/kg, ip administered 40 mins before CFA challenge measured after 6 hrs2011Journal of natural products, Oct-28, Volume: 74, Issue:10
Antinociceptive properties of bergenin.
AID623673Antinociceptive activity against Freund's complete adjuvant-induced paw inflammation in mouse assessed as reduction in mechanical hyperalgesia at 100 mg/kg, ip administered 40 mins before CFA challenge measured after 2 to 6 hrs2011Journal of natural products, Oct-28, Volume: 74, Issue:10
Antinociceptive properties of bergenin.
AID601491Antibacterial activity against Escherichia coli MTCC 739 at 2000 ug/ml after 24 hrs by agar-well diffusion method2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Evaluation of antioxidant and antimicrobial activities of Bergenin and its derivatives obtained by chemoenzymatic synthesis.
AID1187205Cytotoxicity against human THP1 cells after 24 hrs by MTT assay2014Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
Pyrano-isochromanones as IL-6 inhibitors: synthesis, in vitro and in vivo antiarthritic activity.
AID1464053Stability in pH 1.2 SGF assessed as compound remaining level at 120 mg/mL incubated for 24 hrs at 37 degC by HPLC method2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
Synthesis, pH dependent, plasma and enzymatic stability of bergenin prodrugs for potential use against rheumatoid arthritis.
AID609794Antioxidant activity assessed as ABTS free radical scavenging activity at 200 uM2011Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16
Synthesis and antiglycation potentials of bergenin derivatives.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID623706Toxicity in mouse assessed as change in general appearance at 100 mg/kg, ip for seven consecutive days relative to control2011Journal of natural products, Oct-28, Volume: 74, Issue:10
Antinociceptive properties of bergenin.
AID1311778Antiinflammatory activity against LPS-stimulated mouse RAW264.7 cells assessed as downregulation of iNOS levels by ELISA2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
Anti-inflammatory polyphenol constituents derived from Cissus pteroclada Hayata.
AID623677Antinociceptive activity against Freund's complete adjuvant-induced paw inflammation in mouse assessed as reduction in paw edema at 50 mg/kg, ip administered 40 mins before CFA challenge measured after 6 hrs2011Journal of natural products, Oct-28, Volume: 74, Issue:10
Antinociceptive properties of bergenin.
AID623696Toxicity in mouse assessed as renal function measuring serum creatinine level at 50 mg/kg, ip for seven consecutive days relative to control2011Journal of natural products, Oct-28, Volume: 74, Issue:10
Antinociceptive properties of bergenin.
AID623676Antinociceptive activity against Freund's complete adjuvant-induced paw inflammation in mouse assessed as reduction in paw edema at 50 mg/kg, ip administered 40 mins before CFA challenge measured after 4 hrs2011Journal of natural products, Oct-28, Volume: 74, Issue:10
Antinociceptive properties of bergenin.
AID1187207Therapeutic index, ratio of cytotoxic IC50 for human THP1 cells by MTT assay to IC50 for inhibition of LPS-induced IL6 production in human THP1 cells2014Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
Pyrano-isochromanones as IL-6 inhibitors: synthesis, in vitro and in vivo antiarthritic activity.
AID1187200Solubility in water2014Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
Pyrano-isochromanones as IL-6 inhibitors: synthesis, in vitro and in vivo antiarthritic activity.
AID1187220Antiarthritic activity in DBA/1J mouse collagen-induced arthritis model assessed as reduction in paw swelling at 30 mg/kg, po administered once daily for 49 days starting from onset of disease2014Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
Pyrano-isochromanones as IL-6 inhibitors: synthesis, in vitro and in vivo antiarthritic activity.
AID623675Antinociceptive activity against Freund's complete adjuvant-induced paw inflammation in mouse assessed as reduction in paw edema at 50 mg/kg, ip administered 40 mins before CFA challenge measured after 2 hrs2011Journal of natural products, Oct-28, Volume: 74, Issue:10
Antinociceptive properties of bergenin.
AID609797Antiglycation activity in bovine serum albumin assessed as inhibition of fructosamines formation at 200 uM in presence of glucose2011Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16
Synthesis and antiglycation potentials of bergenin derivatives.
AID1464042Inhibition of IL6 (unknown origin)2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
Synthesis, pH dependent, plasma and enzymatic stability of bergenin prodrugs for potential use against rheumatoid arthritis.
AID400670Inhibition of monoclonal antibody ADP360/HIV1 gp120 N-terminal interaction1996Journal of natural products, Jun, Volume: 59, Issue:6
Constituents of Ardisia japonica and their in vitro anti-HIV activity.
AID1311782Inhibition of NFkappaB signaling pathway in LPS-stimulated mouse RAW264.7 cells by ELISA2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
Anti-inflammatory polyphenol constituents derived from Cissus pteroclada Hayata.
AID1187211Antiinflammatory activity in BALB/c mouse assessed as serum IL6 level at 100 mg/kg, po qd for 5 days followed by LPS challenge 1 hr after last compound dose on fifth day and measured 4 hrs post LPS challenge by ELISA method (Rvb = 410 +/- 95 pg/mL)2014Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
Pyrano-isochromanones as IL-6 inhibitors: synthesis, in vitro and in vivo antiarthritic activity.
AID623715Toxicity in mouse assessed as edema in gastric mucosa at 100 mg/kg, ip for seven consecutive days relative to control2011Journal of natural products, Oct-28, Volume: 74, Issue:10
Antinociceptive properties of bergenin.
AID609802Antiglycation activity assessed as inhibition of advanced glycation end product formation2011Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16
Synthesis and antiglycation potentials of bergenin derivatives.
AID1187228Antiarthritic activity in DBA/1J mouse collagen-induced arthritis model assessed as reduction in IL-1beta level at 3 to 30 mg/kg, po administered once daily for 49 days starting from onset of disease and measured after 3 to 49 days of disease onset by ELI2014Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
Pyrano-isochromanones as IL-6 inhibitors: synthesis, in vitro and in vivo antiarthritic activity.
AID656846Antiinflammatory activity in mouse J774.2 cells assessed as inhibition of LPS-induced NO production at 60 uM after 48 hrs by spectrophotometry2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Synthesis of new bergenin derivatives as potent inhibitors of inflammatory mediators NO and TNF-α.
AID623701Toxicity in mouse assessed as gastric ulcer at 50 mg/kg, ip for seven consecutive days relative to control2011Journal of natural products, Oct-28, Volume: 74, Issue:10
Antinociceptive properties of bergenin.
AID1311759Cytotoxicity against LPS-stimulated mouse RAW264.7 cells assessed as reduction in cell viability at 50 umol/L after 24 hrs by MTT assay2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
Anti-inflammatory polyphenol constituents derived from Cissus pteroclada Hayata.
AID402065Enhancement of norepinephrine-induced lipolysis in cell-free system consisting endogenous lipid droplets from Wistar rat fat cells assessed as free fatty acid release per mL of packed fat cells after 1 hr in presence of hormone-sensitive lipase1998Journal of natural products, Aug, Volume: 61, Issue:8
Norepinephrine-augmenting lipolytic effectors from Astilbe thunbergii rhizomes.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID315607Growth inhibition of human BGC823 cells at 10 uM after 72 hrs by MTT assay relative to control2008Bioorganic & medicinal chemistry, Feb-01, Volume: 16, Issue:3
Studies on the chemical constituents and anticancer activity of Saxifraga stolonifera (L) Meeb.
AID1464044Solubility in pH 1.0 buffer2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
Synthesis, pH dependent, plasma and enzymatic stability of bergenin prodrugs for potential use against rheumatoid arthritis.
AID623678Antinociceptive activity against Freund's complete adjuvant-induced paw inflammation in mouse assessed as reduction in paw edema at 100 mg/kg, ip administered 40 mins before CFA challenge measured after 2 hrs2011Journal of natural products, Oct-28, Volume: 74, Issue:10
Antinociceptive properties of bergenin.
AID623688Inhibition of TNF-alpha production in Freund's complete adjuvant-induced mouse at 50 mg/kg, ip administered 40 mins before CFA challenge measured after 2 hrs by ELISA2011Journal of natural products, Oct-28, Volume: 74, Issue:10
Antinociceptive properties of bergenin.
AID1853443Inhibition of ConA-induced proliferation of BALB/c mouse splenocyte at 10 uM incubated for 48 hrs by CCK-8 assay relative to control2021RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11
Synthesis and biological evaluation of bergenin derivatives as new immunosuppressants.
AID1187214Antiarthritic activity in BALB/c mouse assessed as reduction in SRBC-induced blood IFNgamma level administered orally once daily for 14 days measured 4 hrs post last dose by ELISA method2014Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
Pyrano-isochromanones as IL-6 inhibitors: synthesis, in vitro and in vivo antiarthritic activity.
AID623670Neurotoxicity in mouse assessed as effect on motor coordination at 100 mg/kg, ip after 40 mins by open field test2011Journal of natural products, Oct-28, Volume: 74, Issue:10
Antinociceptive properties of bergenin.
AID1464045Solubility in pH 3.0 buffer2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
Synthesis, pH dependent, plasma and enzymatic stability of bergenin prodrugs for potential use against rheumatoid arthritis.
AID623691Inhibition of IL10 production in Freund's complete adjuvant-induced C57BL/6 mouse paw at 100 mg/kg, ip administered 40 mins before CFA challenge measured after 3 hrs by ELISA2011Journal of natural products, Oct-28, Volume: 74, Issue:10
Antinociceptive properties of bergenin.
AID1464049Stability in pH 1.2 HCl buffer assessed as compound remaining level at 120 mg/mL incubated for 24 hrs at 37 degC by HPLC method2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
Synthesis, pH dependent, plasma and enzymatic stability of bergenin prodrugs for potential use against rheumatoid arthritis.
AID1464048Distribution coefficient, log D of the compound in PBS/n-octanol at pH 7.4 at 25 degC by HPLC method2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
Synthesis, pH dependent, plasma and enzymatic stability of bergenin prodrugs for potential use against rheumatoid arthritis.
AID402068Stimulation of ACTH-induced lipolysis in Wistar rat fat cells assessed as free fatty acid release per mL of packed fat cells at 100 ug after 1 hr relative to ACTH1998Journal of natural products, Aug, Volume: 61, Issue:8
Norepinephrine-augmenting lipolytic effectors from Astilbe thunbergii rhizomes.
AID1187225Antiarthritic activity in DBA/1J mouse collagen-induced arthritis model assessed as reduction in anticollagen antibody IgG2a level at 3 to 30 mg/kg, po administered once daily for 49 days starting from onset of disease and measured after 49 days of diseas2014Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
Pyrano-isochromanones as IL-6 inhibitors: synthesis, in vitro and in vivo antiarthritic activity.
AID1464051Stability in pH 4.0 phosphate buffer assessed as compound remaining level at 120 mg/mL incubated for 24 hrs at 37 degC by HPLC method2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
Synthesis, pH dependent, plasma and enzymatic stability of bergenin prodrugs for potential use against rheumatoid arthritis.
AID315608Growth inhibition of human BGC823 cells at 50 uM after 72 hrs by MTT assay relative to control2008Bioorganic & medicinal chemistry, Feb-01, Volume: 16, Issue:3
Studies on the chemical constituents and anticancer activity of Saxifraga stolonifera (L) Meeb.
AID623700Toxicity in mouse assessed as gastric inflammation at 50 mg/kg, ip for seven consecutive days relative to control2011Journal of natural products, Oct-28, Volume: 74, Issue:10
Antinociceptive properties of bergenin.
AID1187224Antiarthritic activity in DBA/1J mouse collagen-induced arthritis model assessed as reduction in anticollagen antibody IgG1 level at 3 to 30 mg/kg, po administered once daily for 49 days starting from onset of disease and measured after 49 days of disease2014Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
Pyrano-isochromanones as IL-6 inhibitors: synthesis, in vitro and in vivo antiarthritic activity.
AID1059454Antioxidant activity assessed as trolox equivalent of APPH-induced peroxyl radical scavenging activity at 5 to 20 uM measured every 1 min for 120 mins by ORAC fluorescence assay2013Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24
Synthesis, antioxidant capacity, and structure-activity relationships of tri-O-methylnorbergenin analogues on tyrosinase inhibition.
AID1187204Inhibition of LPS-induced nitric oxide production in human THP1 cells at 10 uM after 24 hrs by Griess assay2014Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
Pyrano-isochromanones as IL-6 inhibitors: synthesis, in vitro and in vivo antiarthritic activity.
AID1187215Antiarthritic activity in BALB/c mouse assessed as reduction in SRBC-induced blood IL4 level administered orally once daily for 14 days measured 4 hrs post last dose by ELISA method2014Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
Pyrano-isochromanones as IL-6 inhibitors: synthesis, in vitro and in vivo antiarthritic activity.
AID1187201Inhibition of LPS-induced IL6 production in human THP1 cells after 24 hrs2014Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
Pyrano-isochromanones as IL-6 inhibitors: synthesis, in vitro and in vivo antiarthritic activity.
AID609799Antiglycation activity assessed as inhibition of dicarbonyl compounds formation at 200 uM2011Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16
Synthesis and antiglycation potentials of bergenin derivatives.
AID1187237Inhibition of NFkappaB p65/rel expression in human THP1 cells at 20 to 100 uM by Western blotting method2014Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
Pyrano-isochromanones as IL-6 inhibitors: synthesis, in vitro and in vivo antiarthritic activity.
AID1187206Cytotoxicity against human THP1 cells after 48 hrs by MTT assay2014Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
Pyrano-isochromanones as IL-6 inhibitors: synthesis, in vitro and in vivo antiarthritic activity.
AID623699Toxicity in mouse assessed as leukogram at 50 mg/kg, ip for seven consecutive days relative to control2011Journal of natural products, Oct-28, Volume: 74, Issue:10
Antinociceptive properties of bergenin.
AID1464047Partition coefficient, log P of the compound in water/n-octanol at pH 7.4 at 25 degC by HPLC method2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
Synthesis, pH dependent, plasma and enzymatic stability of bergenin prodrugs for potential use against rheumatoid arthritis.
AID623711Toxicity in mouse assessed as leukogram at 100 mg/kg, ip for seven consecutive days relative to control2011Journal of natural products, Oct-28, Volume: 74, Issue:10
Antinociceptive properties of bergenin.
AID402069Stimulation of ACTH-induced lipolysis in Wistar rat fat cells assessed as free fatty acid release per mL of packed fat cells at 1000 ug after 1 hr relative to ACTH1998Journal of natural products, Aug, Volume: 61, Issue:8
Norepinephrine-augmenting lipolytic effectors from Astilbe thunbergii rhizomes.
AID623703Toxicity in mouse assessed as edema in gastric mucosa at 50 mg/kg, ip for seven consecutive days relative to control2011Journal of natural products, Oct-28, Volume: 74, Issue:10
Antinociceptive properties of bergenin.
AID609795Antiglycation activity assessed as inhibition of Schiff-base formation at 200 uM2011Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16
Synthesis and antiglycation potentials of bergenin derivatives.
AID1187227Antiarthritic activity in DBA/1J mouse collagen-induced arthritis model assessed as reduction in IL6 level at 3 to 30 mg/kg, po administered once daily for 49 days starting from onset of disease and measured after 3 to 49 days of disease onset by ELISA me2014Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
Pyrano-isochromanones as IL-6 inhibitors: synthesis, in vitro and in vivo antiarthritic activity.
AID623697Toxicity in mouse assessed as liver function measuring serum ALT level at 50 mg/kg, ip for seven consecutive days relative to control2011Journal of natural products, Oct-28, Volume: 74, Issue:10
Antinociceptive properties of bergenin.
AID1311783Antiinflammatory activity against LPS-stimulated mouse RAW264.7 cells assessed as downregulation of COX2 levels by ELISA2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
Anti-inflammatory polyphenol constituents derived from Cissus pteroclada Hayata.
AID623712Toxicity in mouse assessed as gastric inflammation at 100 mg/kg, ip for seven consecutive days relative to control2011Journal of natural products, Oct-28, Volume: 74, Issue:10
Antinociceptive properties of bergenin.
AID623672Antinociceptive activity against Freund's complete adjuvant-induced paw inflammation in mouse assessed as reduction in mechanical hyperalgesia at 50 mg/kg, ip administered 40 mins before CFA challenge measured after 2 to 6 hrs2011Journal of natural products, Oct-28, Volume: 74, Issue:10
Antinociceptive properties of bergenin.
AID623695Toxicity in mouse assessed as renal function measuring serum urea level at 50 mg/kg, ip for seven consecutive days relative to control2011Journal of natural products, Oct-28, Volume: 74, Issue:10
Antinociceptive properties of bergenin.
AID402070Inhibition of insulin-induced lipogenesis from [U-14C]glucose in Wistar rat fat cells after 1 hr by liquid scintillation counting1998Journal of natural products, Aug, Volume: 61, Issue:8
Norepinephrine-augmenting lipolytic effectors from Astilbe thunbergii rhizomes.
AID1464052Stability in pH 6.8 PBS buffer assessed as compound remaining level at 120 mg/mL incubated for 24 hrs at 37 degC by HPLC method2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
Synthesis, pH dependent, plasma and enzymatic stability of bergenin prodrugs for potential use against rheumatoid arthritis.
AID1187209Antiinflammatory activity in BALB/c mouse assessed as serum TNFalpha level at 100 mg/kg, po qd for 5 days followed by LPS challenge 1 hr after last compound dose on fifth day and measured 4 hrs post LPS challenge by ELISA method (Rvb = 717 +/- 218 pg/mL)2014Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
Pyrano-isochromanones as IL-6 inhibitors: synthesis, in vitro and in vivo antiarthritic activity.
AID1464054Stability in pH 6.8 SIF assessed as compound remaining level at 120 mg/mL incubated for 24 hrs at 37 degC by HPLC method2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
Synthesis, pH dependent, plasma and enzymatic stability of bergenin prodrugs for potential use against rheumatoid arthritis.
AID601492Antibacterial activity against Klebsiella pneumoniae MTCC 139 at 2000 ug/ml after 24 hrs by agar-well diffusion method2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Evaluation of antioxidant and antimicrobial activities of Bergenin and its derivatives obtained by chemoenzymatic synthesis.
AID601455Inhibition of xanthine oxidase assessed as reduction of uric acid production from xanthine at 10 to 50 uM preincubated for 15 mins measured after 30 mins by spectrophotometry2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Evaluation of antioxidant and antimicrobial activities of Bergenin and its derivatives obtained by chemoenzymatic synthesis.
AID601454Antioxidant activity assessed as DPPH free radical scavenging activity at 200 to 1000 uM after 5 mins2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Evaluation of antioxidant and antimicrobial activities of Bergenin and its derivatives obtained by chemoenzymatic synthesis.
AID402066Effect on lipolysis in cell-free system consisting sonicated lipid droplets assessed as free fatty acid release at 1000 ug in presence of hormone-sensitive lipase relative to untreated control1998Journal of natural products, Aug, Volume: 61, Issue:8
Norepinephrine-augmenting lipolytic effectors from Astilbe thunbergii rhizomes.
AID1187198Inhibition of concanavalin A-induced cell proliferation of T cells (unknown origin) at 10 uM after 72 hrs by MTT assay2014Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
Pyrano-isochromanones as IL-6 inhibitors: synthesis, in vitro and in vivo antiarthritic activity.
AID623689Inhibition of TNF-alpha production in Freund's complete adjuvant-induced mouse at 100 mg/kg, ip administered 40 mins before CFA challenge measured after 2 hrs by ELISA2011Journal of natural products, Oct-28, Volume: 74, Issue:10
Antinociceptive properties of bergenin.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1187203Inhibition of LPS-induced IL-1beta production in human THP1 cells at 10 uM after 24 hrs2014Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
Pyrano-isochromanones as IL-6 inhibitors: synthesis, in vitro and in vivo antiarthritic activity.
AID1424162Antiproliferative activity against human MCF7 cells incubated for 48 to 72 hrs by MTT assay2017European journal of medicinal chemistry, Jun-16, Volume: 133Synthesis and in vitro and in vivo antitumour activity study of 11-hydroxyl esterified bergenin/cinnamic acid hybrids.
AID1311758Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability at 50 umol/L after 24 hrs by MTT assay2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
Anti-inflammatory polyphenol constituents derived from Cissus pteroclada Hayata.
AID623642Antinociceptive activity against formalin-induced pain in mouse assessed as paw licking during late phase (10 to 60 mins) at 50 mg/kg, ip administered 40 mins before formalin challenge2011Journal of natural products, Oct-28, Volume: 74, Issue:10
Antinociceptive properties of bergenin.
AID1424160Antiproliferative activity against human A549 cells incubated for 48 to 72 hrs by MTT assay2017European journal of medicinal chemistry, Jun-16, Volume: 133Synthesis and in vitro and in vivo antitumour activity study of 11-hydroxyl esterified bergenin/cinnamic acid hybrids.
AID400665Inhibition of monoclonal antibody ADP358/HIV1 gp120 interaction at 500 mg/mL1996Journal of natural products, Jun, Volume: 59, Issue:6
Constituents of Ardisia japonica and their in vitro anti-HIV activity.
AID1853449Inhibition of ConA-induced IL-4 secretion in BALB/c mouse splenocyte at 10 uM incubated for 48 hrs by ELISA relative to control2021RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11
Synthesis and biological evaluation of bergenin derivatives as new immunosuppressants.
AID1187217Immunosuppressive activity in BALB/c mouse assessed as reduction in SRBC-induced humoral immunity by measuring IgM level at 3 to 30 mg/kg, po administered once daily for 14 days measured 4 hrs post last dose2014Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
Pyrano-isochromanones as IL-6 inhibitors: synthesis, in vitro and in vivo antiarthritic activity.
AID1187238Inhibition of IKKbeta expression in human THP1 cells at 20 to 100 uM by Western blotting method2014Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
Pyrano-isochromanones as IL-6 inhibitors: synthesis, in vitro and in vivo antiarthritic activity.
AID656844Cytotoxicity against mouse 3T3 cells at 100 uM after 72 hrs by MTT assay2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Synthesis of new bergenin derivatives as potent inhibitors of inflammatory mediators NO and TNF-α.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (155)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (2.58)18.7374
1990's9 (5.81)18.2507
2000's29 (18.71)29.6817
2010's78 (50.32)24.3611
2020's35 (22.58)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 58.21

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index58.21 (24.57)
Research Supply Index5.07 (2.92)
Research Growth Index5.25 (4.65)
Search Engine Demand Index93.97 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (58.21)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews6 (3.80%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other152 (96.20%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]